ReviewCurrent opinion in pediatrics2016
Understanding autoimmunity of vitiligo and alopecia areata.
Review in Current opinion in pediatrics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 108 citations in OpenAlex.
- Alopecia areata: current concepts.Wiener klinische Wochenschrift · 2026Review
- Risk Factors for Pediatric Alopecia Areata: Clinical and Biochemical Findings from a Case - Control Study.Dermatology practical & conceptual · 2026Article
- Integrative Transcriptomic and Genetic Analysis PrioritizesClinical, cosmetic and investigational dermatology · 2026Article
- Prevalence and Association of Autoimmune Comorbidities Among Adults with Vitiligo: A Systematic Literature Review and Meta-analysis of USA-Based Studies.Dermatology and therapy · 2025Review
- Deciphering Depigmentation: Mouse Models for Vitiligo Research.The Journal of investigative dermatology · 2025Review
- Association of Vitiligo With Autoimmune Disorders: A Bidirectional Two-Sample and Summary-Based Mendelian Randomization Study.Journal of cosmetic dermatology · 2025Article
- Hair regrowth in alopecia areata and re-pigmentation in vitiligo in response to treatment: Commonalities and differences.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- Co-regulatory mechanisms and potential markers of oxidative stress-related genes in vitiligo and alopecia areata.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Late-Onset Reactions after Hyaluronic Acid Dermal Fillers: A Consensus Recommendation on Etiology, Prevention and Management.Dermatology and therapy · 2024Review
- Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences.International journal of molecular sciences · 2024Review
- Association of vitiligo with multiple cutaneous and extra-cutaneous autoimmune diseases: a nationwide cross-sectional study.Archives of dermatological research · 2023Article
- Exploring Mast Cell-CD8 T Cell Interactions in Inflammatory Skin Diseases.International journal of molecular sciences · 2023Review
- Vitiligo-Thyroid Disease Association: When, in Whom, and Why Should It Be Suspected? A Systematic Review.Journal of personalized medicine · 2022Review
- Review
- Videodermoscopic Changes of the Hair in Vitiligo Lesions in Relation to Disease Duration.Dermatology practical & conceptual · 2022Article
- CHAC1 as a novel biomarker for distinguishing alopecia from other dermatological diseases and determining its severity.IET systems biology · 2022Article
- RNAi-based modulation of IFN-γ signaling in skin.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Study of Novel Furocoumarin Derivatives on Anti-Vitiligo Activity, Molecular Docking and Mechanism of Action.International journal of molecular sciences · 2022Article
- Vitiligo Co-Localized Over a Patch of Alopecia Areata in Two Patients: More Than a Coincidence?Dermatology practical & conceptual · 2022Article
- Immune Activities in Choroids of Visually Impaired Smyth Chickens With Autoimmune Vitiligo.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewVitiligo and alopecia areata are common, disfiguring skin diseases. Treatment options are limited and include nontargeted approaches, such as corticosteroids, topical calcineurin inhibitors, narrow band ultraviolet B phototherapy, and other immune-modifying agents. The purpose of this article is to review shared, novel mechanisms between vitiligo and alopecia areata, as well as discuss how they inform the development of future targeted treatments. RECENT
findingsVitiligo and alopecia areata are both autoimmune diseases, and striking similarities in pathogenesis have been identified at the level of both the innate and adaptive immune system. Increased reactive oxygen species and high cellular stress level have been suggested as the initiating trigger of the innate immune system in both diseases, and genome-wide association studies have implicated risk alleles that influence both innate and adaptive immunity. Most importantly, mechanistic studies in mouse models of vitiligo and alopecia areata have specifically implicated an interferon (IFN)γ-driven immune response, including IFNγ, IFNγ-induced chemokines, and cytotoxic CD8 T cells as the main drivers of disease pathogenesis. These recent discoveries may reveal an effective strategy to develop new treatments, and several proof-of-concept clinical studies support this hypothesis. SUMMARY: The identification of IFNγ-driven immune signaling pathways has enabled discoveries of potential new treatments for vitiligo and alopecia areata, and supports initiation of larger clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.